

## Policy Tracker Archive

117<sup>th</sup> United States Congress (January 3<sup>rd</sup>, 2021 – March 31<sup>st</sup>, 2022)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Accountability and Oversight	Allow government to regulate/require disclosure of patient assistance	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Require the inclusion of manufacturer cost-sharing coupons in the determination of Average Sales Price for drugs and biologics reimbursed under Medicare Part B.	<a href="#">Rep. Peters (D-CA)</a>
Accountability and Oversight	Ensure 340B program is providing care for the low-income patients it is intended to serve	[Closing Loopholes for Orphan Drugs Act; Introduced 02/04/2021] Revise the 340B drug discount program to exclude discounting orphan drugs that are not being used to treat rare conditions.	<a href="#">Rep. Welch (D-VT)</a>
Accountability and Oversight	Ensure 340B program is providing care for the low-income patients it is intended to serve	[PROTECT 340B Act of 2021; Introduced 07/09/2021] Ensure that entities covered by the 340B drug discount program are using the discount to properly benefit low income patients.	<a href="#">Rep. McKinley (R-WV)</a>
Accountability and Oversight	Ensure 340B program is providing care for the low-income patients it is intended to serve	[Vital Medication Affordability Act; Introduced 09/23/2021] Require centers that participates in the 340B program to establish written practices to make insulin and injectable epinephrine available to low-income patients at or below the discounted 340B price paid by the center.	<a href="#">Sen. Kennedy (R-LA)</a>
Accountability and Oversight	Ensure 340B program is providing care for the low-income patients it is intended to serve	[Drug Price Transparency and Accountability Act; Introduced 09/30/2021] Enhance of reporting and transparency requirements for the 340B Drug Pricing Program.	<a href="#">Rep. Rosendale (R-MT)</a>
Accountability and Oversight	Ensure biosimilars cannot be paid more than their reference biologic product	[Lower Costs, More Cures Act of 2021; Introduced 04/21/2021] Limit the payment amount for biosimilars during the initial period.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>
Accountability and Oversight	Ensure biosimilars cannot be paid more than their reference biologic product	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Require Medicare payment for biosimilar products during the initial period be equal to or less than the price of the reference biologic product.	<a href="#">Rep. Peters (D-CA)</a>
Accountability and Oversight	Ensure biosimilars cannot be paid more than their	[Lower Costs, More Cures Act of 2021; Introduced 04/21/2021] Limit the payment amount for biosimilars during the initial period.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
	reference biologic product		
Accountability and Oversight	Establish evidence based measures of quality	[Elijah E. Cummings Lower Drug Costs Now Act; Introduced 04/22/2021] Establish pharmacy quality measures under part D.	<a href="#">Rep. Pallone (D-NJ)</a>
Accountability and Oversight	Establish evidence based measures of quality	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Establish pharmacy quality measures under Medicare Part D.	<a href="#">Rep. Peters (D-CA)</a>
Accountability and Oversight	Health Plan Transparency	[Lower Costs, More Cures Act of 2021; Introduced 04/21/2021] Require PDPs and MA-PD plans to report fraud, waste, and abuse to HHS.	<a href="#">American Enterprise Institute</a>
Accountability and Oversight	Health Plan Transparency	[Pharmacy DIR Reform to Reduce Senior Drug Costs Act; Introduced 05/25/2021] Require prescription drug plans to report price concessions or incentive payments that are made after payment for covered drugs at the point of sale, including by contracted intermediaries, to the pharmacy at least annually.	<a href="#">Rep. Welch (D-VT)</a>
Accountability and Oversight	Health Plan Transparency	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Require prescription drug plans and Medicare Advantage prescription drug plans to report potential fraud, waste, and abuse to HHS.	<a href="#">Rep. Peters (D-CA)</a>
Accountability and Oversight	Manufacturer Transparency	[Fair Accountability and Innovative Research Drug Pricing Act of 2021; Introduced 03/23/2021] Require manufacturers to report on justification for certain drug price increases.	<a href="#">Sen. Baldwin (D-WI)</a>
Accountability and Oversight	Manufacturer Transparency	[Lower Costs, More Cures Act of 2021, Introduced 04/21/2021] Require manufacturers to report on justification of certain drug price increases.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>
Accountability and Oversight	Manufacturer Transparency	[Lower Costs, More Cures Act of 2021, Introduced 04/21/2021] Make prescription drug marketing sample information available to oversight agencies, researchers, payers, and the public.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>
Accountability and Oversight	Manufacturer Transparency	[Lower Costs, More Cures Act of 2021, Introduced 04/21/2021] Conduct audits and surveys of manufacturer price and drug product information under the Medicaid Drug Rebate Program.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>
Accountability and Oversight	Manufacturer Transparency	[Elijah E. Cummings Lower Drug Costs Now Act; Introduced 04/22/2021] Require	<a href="#">Rep. Pallone (D-NJ)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		manufacturers to justify to HHS certain drug price increases.	
Accountability and Oversight	Manufacturer Transparency	[Affordable Medications Act; Introduced 05/27/2021] Require drug manufacturers to submit an annual report with data on approved drugs with respect to the previous calendar year, including the wholesale acquisition cost, net average price realized by pharmacy benefit managers, and net price of the drug charged to purchasers.	<a href="#">Sen. Smith (D-MN)</a>
Accountability and Oversight	Manufacturer Transparency	[Affordable Medications Act; Introduced 05/27/2021] Require pharmaceutical companies to submit pricing and sales information to the Inspector General on a quarterly basis to identify prescription drug price hikes.	<a href="#">Sen. Smith (D-MN)</a>
Accountability and Oversight	Manufacturer Transparency	[Affordable Medications Act; Introduced 05/27/2021] Require drug manufacturers to disclose the wholesale acquisition cost for a 30-day supply of the drug whenever a manufacturer communicates with a health care practitioner about a drug they manufacture.	<a href="#">Sen. Smith (D-MN)</a>
Accountability and Oversight	Manufacturer Transparency	[SPIKE Act; Introduced 07/13/2021] Require CMS to determine at least annually whether certain covered drugs under Medicare were subject to a price increase that exceeded specified thresholds. Drug manufacturers must submit justifications for such price increases to the CMS, subject to civil penalties.	<a href="#">Rep. Horsford (D-NV)</a>
Accountability and Oversight	Manufacturer Transparency	[Matt's Act; Introduced 07/29/2021] Require manufacturers of insulin drugs to publish the average net price of each insulin product on a quarterly basis.	<a href="#">Rep. Fortenberry (R-NE)</a>
Accountability and Oversight	Manufacturer Transparency	[Medicare Negotiation and Competitive Licensing Act of 2021; Introduced 07/29/2021] Require pharmaceutical companies to submit pricing and sales information to the Inspector General on a quarterly basis.	<a href="#">Rep. Doggett (D-TX)</a>
Accountability and Oversight	Manufacturer Transparency	[Reduced Cost and Continued Cures Act of 2021; Introduced 09/10/2021] Require drug manufacturers to submit justification for drug prices if the drug has a larger increase in price, high spending under Medicare and Medicaid, or a high launch price.	<a href="#">Rep. Peters (D-CA)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Accountability and Oversight	Manufacturer Transparency	[Reduced Cost and Continued Cures Act of 2021; Introduced 09/10/2021] Require audits of drug pricing and product information reported to the Medicaid Drug Rebate Program by drug manufacturers.	<a href="#">Rep. Peters (D-CA)</a>
Accountability and Oversight	PBM Transparency	[Improving Transparency to Lower Drug Costs Act of 2021; Introduced 06/01/2021] Require CMS to publish certain payment information regarding pharmacy benefit managers (PBMs) and prescription drugs, including generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies.	<a href="#">Rep. Spanberger (D-VA)</a>
Accountability and Oversight	PBM Transparency	[Reduced Costs and Continued Cures Act of 2021; Introduce 09/10/2021] Require HHS to publicly report on PBMs' ability to negotiate rebates, discounts, and price concessions and the amount of these rebates, discounts, and price concessions that are passed on to plan sponsors.	<a href="#">Rep. Peters (D-CA)</a>
Accountability and Oversight	PBM Transparency	[Reduced Costs and Continued Cures Act of 2021; Introduce 09/10/2021] Expand PBM transparency requirements including, but not limited to, the reporting of bona fide service fees that PBMs receive from PDP sponsors, health benefit plans, managed care entities, and drug manufacturers.	<a href="#">Rep. Peters (D-CA)</a>
Accountability and Oversight	PBM Transparency	[Reduced Costs and Continued Cures Act of 2021; Introduce 09/10/2021] Prohibit contracts between health plans and PBMs unless PBMs submit periodic quality reports to health plan sponsors. Reports include, but are not limited to, information on the dispensing of covered drugs, total gross drug spending, and the amount received from drug manufacturers.	<a href="#">Rep. Peters (D-CA)</a>
Accountability and Oversight	Provider Transparency	[Hospital Transparency Compliance Act; Introduced 03/03/2022] Enforce compliance with hospital price transparency requirements.	<a href="#">Sen. Kennedy (R-LA)</a>
Accountability and Oversight	Provider Transparency	[Health Care Equality and Modernization Act of 2022; Introduced 03/28/2022] Require publishing of cash prices made to healthcare providers that they charge for furnishing of health care items and services through a publicly accessible website.	<a href="#">Rep. Sessions (R-TX)</a>
Foster Competition	Incentivize generic and biosimilar entry	[Short on Competition Act; Introduced 03/23/2021] Allow for the expedited	<a href="#">Sen. Klobuchar (D-MN)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		approval and temporary importation of generic prescription drugs in the case of noncompetitive drug markets (fewer than five holders of approved applications for brand or generic versions of the drug, drug has been approved for at least 10 years, or patents on the active ingredient of a drug have expired).	
Foster Competition	Incentivize generic and biosimilar entry	[BLOCKING Act of 2021; Introduced 04/26/2021] Authorize the FDA to approve a subsequent generic drug application prior to a first applicant's first date of commercial marketing if (1) the subsequent application is ready for full approval, (2) a first applicant's application has been pending for at least 30 months, and (3) the approval of a first applicant's application is not precluded by patent infringement claims asserted against that first applicant.	<a href="#">Rep. Schrader (D-OR)</a>
Foster Competition	Incentivize generic and biosimilar entry	[STOP GAMES Act of 2021; Introduced 04/26/2021] Clarify the process for denying certain petitions whose primary purpose is to delay the approval of a pending new or generic drug application. If the FDA finds that delay is the primary purpose of the petition, it must refer the matter to the Federal Trade Commission.	<a href="#">Rep. Levin (D-MI)</a>
Foster Competition	Incentivize generic and biosimilar entry	[Protecting Access to Affordable Medicines Act of 2021; Introduced 04/28/2021] Limit additional rebates for non-innovator multiple-source drugs (i.e., generics) in the Medicaid program when the average manufacturer price is less than \$1 to exempt low-cost generic drugs from inflation penalties under the 2015 Bipartisan Budget Act.	<a href="#">Rep. Butterfield (D-NC)</a>
Foster Competition	Incentivize generic and biosimilar entry	[Simplifying the Generic Drug Application Process Act; Introduced 04/29/2021] Remove requirement for a generic drug maker to petition the FDA before seeking market approval for a generic drug that has a different dosage or strength form than an already-approved drug.	<a href="#">Sen. Cassidy (R-LA)</a>
Foster Competition	Incentivize generic and biosimilar entry	[Affordable Medications Act; Introduced 05/27/2021] Modify Bipartisan Congressional Trade Priorities and Accountability Act of 2015 to ensure trade agreements do not	<a href="#">Sen. Smith (D-MN)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		require a party to provide biological product exclusivity of more than 7 years.	
Foster Competition	Incentivize generic and biosimilar entry	[Affordable Medications Act; Introduced 05/27/2021] Includes a 180-day exclusivity period for the generic applicants with first application status.	<a href="#">Sen. Smith (D-MN)</a>
Foster Competition	Incentivize generic and biosimilar entry	[Expanding Access to Affordable Prescription Drugs and Medical Devices Act; Introduced 06/24/2021] Allow the Secretary to provide cooperative agreements and low interest revolving loans to nonprofit generic and essential medicines and device manufacturers.	<a href="#">Sen. Rosen (D-NY)</a>
Foster Competition	Incentivize generic and biosimilar entry	[Enhanced Access to Affordable Medicines Act of 2022; Introduced 03/08/2022] Allow the approval of generic drug applications with labeling temporarily different than the brand name drug.	<a href="#">Rep. Carter (R-GA)</a>
Foster Competition	Incentivize use of biosimilars and generics	[BIOSIM Act; Introduced 04/22/2021] Provide a 5-year payment increase under the Medicare Part B program for biosimilar biological products for which the average sales price and wholesale acquisition cost is less than that of the reference biological product.	<a href="#">Rep. Schrader (D-OR)</a>
Foster Competition	Incentivize use of biosimilars and generics	[Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021; Introduced 04/26/2021] Require Medicare Part D prescription drug plans that use a formulary to include certain generic drugs and biosimilar biological products on such formulary.	<a href="#">Rep. McKinley (R-WV)</a>
Foster Competition	Incentivize use of biosimilars and generics	[Star Rating for Biosimilars Act; Introduced 04/26/2021] Require CMS to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management.	<a href="#">Rep. Tonko (D-NY)</a>
Foster Competition	Incentivize use of biosimilars and generics	[Reduced Cost and Continued Cures Act of 2021; Introduced 09/10/2021] Increase add-on payment for a biosimilar under Medicare Part B from 6% of reference product's ASP to 8% for a period of five years.	<a href="#">Rep. Peters (D-CA)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Foster Competition	Incentivize use of biosimilars and generics	[Reduced Cost and Continued Cures Act of 2021; Introduced 09/10/2021] Including a new measure of the 5-star rating system under Medicare Advantage that focuses on beneficiary access to biosimilars.	<a href="#">Rep. Peters (D-CA)</a>
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Protecting Consumer Access to Generic Drugs Act of 2021; Introduced 01/04/2021] Prohibit branded manufacturers from compensating generic manufacturers for delaying the entry of a generic drug into the market and prohibit biologic manufacturers from compensating biosimilar and interchangeable product manufacturers for delaying entry of a biosimilar or interchangeable product.	<a href="#">Rep. Rush (D-IL)</a>
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Lower Costs, More Cures Act of 2021; Introduced 04/21/2021] Prohibit pay-for-delay agreements.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Stop STALLING ACT; Introduced 04/28/2021] Authorize the Federal Trade Commission to sue an individual or entity that submits an objectively baseless petition to the FDA in an attempt to interfere with a competitor's application for market approval of a drug.	<a href="#">Sen. Klobuchar (D-MN)</a>
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Preserve Access to Affordable Generics and Biosimilars Act; Introduced 04/28/2021] Prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market and prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar and interchangeable biological products.	<a href="#">Sen. Klobuchar (D-MN)</a>
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Affordable Prescriptions for Patients Act of 2021; Introduced 04/28/2021] Prohibit product hopping.	<a href="#">Sen. Cornyn (R-TX)</a>
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act; Introduced 04/28/2021] Set limits in certain instances to the number of patents that the manufacturer of a biologic drug can assert in a lawsuit against a company seeking to sell a biosimilar version of that drug.	<a href="#">Rep. Johnson (D-GA)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Affordable Medications Act; Introduced 05/27/2021] Prohibit compensation for the delay of affordable generics and biosimilars in the form of anything of value or an agreement to limit or forego research, development, manufacturing, marketing, or sales of a generic or biosimilar.	<a href="#">Sen. Smith (D-MN)</a>
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Affordable Medications Act; Introduced 05/27/2021] Disqualify generic applicants from first application status if applicant agrees not to seek approval of its application or not to begin commercial marketing of its drug until a date that is after the expiration of the 180-day exclusivity period awarded to another applicant with respect to such drug.	<a href="#">Sen. Smith (D-MN)</a>
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Establish rules and regulations to end 'pay-for-delay' in which brand name drug manufacturers pay generic manufacturers to delay launch of generic products.	<a href="#">Rep. Peters (D-CA)</a>
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Creation of pathway for the Federal Trade Commission to prevent manufacturers from "product hopping."	<a href="#">Rep. Peters (D-CA)</a>
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Amendment of Section 271 (e) of title 35 of the U.S.C. to further limit patent thickets.	<a href="#">Rep. Peters (D-CA)</a>
Incentivize innovation	Establish a new FDA approval pathway	[Promising Pathway Act; Introduced 05/13/2021] Establishment of an approval pathway for drugs and biologics for the treatment of serious diseases and conditions. Approval pathway would provide early, short-term approval for drugs and biologics that provide substantial evidence of safety and positive therapeutic benefit. Expands the evidence requirements to allow for use of "scientifically-substantially-surrogates" or surrogate endpoints to predict clinical benefit.	<a href="#">Sen. Braun (R-IN)</a>
Incentivize innovation	Establish a new FDA approval pathway	[Promising Pathway Act; Introduced 05/13/2021] Provisional approval granted under the Promising Pathway can be up to a maximum of 2 years, renewable every 2 years, for up to 6 years. Full approval is granted when the drug or biologic has at	<a href="#">Sen. Braun (R-IN)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		least a 15% improvement in an important endpoint as compared to other therapies.	
Incentivize innovation	Establish a new FDA approval pathway	[ADAPT Act; Introduced 05/13/2021] Authorize the FDA to create an accelerated approval pathway for drugs currently approved for sale in certain countries and that meet certain criteria, including the drug is safe and effective, all relevant U.S. patents or legal exclusivities have expired, and the United States has a public health or unmet medical need for the drug.	<a href="#">Sen. Braun (R-IN)</a>
Incentivize innovation	Establish a new FDA approval pathway	[Equal Access to Therapeutics Act; Introduced 02/07/2022] Allow accelerated approval pathway to be used for a drug treating a serious or life-threatening disease or condition, including a fast track product.	<a href="#">Rep. Davis (R-IL)</a>
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Lower Costs, More Cures Act of 2021; Introduced 04/21/2021] Require that DTC advertisements for drugs and biologics include truthful pricing information.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Lower Costs, More Cures Act of 2021; Introduced 04/21/2021] Require public disclosure of drug discounts to allow comparison of PBMS' ability to negotiate rebates, discounts, remuneration fees, etc.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Health Care PRICE Transparency Act; Introduced 04/29/2021] Require hospitals to publicly report the following pricing information for hospital items or services: a description of each item or service, the gross charge, any payer-specific negotiated charge clearly associated with the name of the third party payer and plan, the de-identified minimum and maximum negotiated charge, the discounted cash price, and any associated billing codes.	<a href="#">Sen. Braun (R-IN)</a>
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Prescription Drug Pricing Dashboard Act; Introduced 05/20/2021] Require CMS to update the Medicare and Medicaid prescription drug pricing dashboards to include specified information, such as data on out-of-pocket costs and drugs with the highest total spending under each program.	<a href="#">Sen. Casey (D-PA)</a>
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[DTC Act of 2021; Introduced 06/24/2021] Require direct-to consumer advertisements for prescription drugs and biologics to include a clear and conspicuous disclosure of	<a href="#">Sen. Durbin (D-IL)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		the wholesale acquisition cost (WAC) for a 30-day supply of the drug.	
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Matt's Act; Introduced 07/29/2021] Require drug manufacturers to publish net prices on the internet on a quarterly basis.	<a href="#">Rep. Fortenberry (R-NE)</a>
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Require HHS to publicly report on PBMs' ability to negotiate rebates, discounts, and price concessions and the amount of these rebates, discounts, and price concessions that are passed on to plan sponsors.	<a href="#">Rep. Peters (D-CA)</a>
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Publish direct and indirect remuneration (DIR) reports to CMS website that are submitted by prescription drug plan sponsors.	<a href="#">Rep. Peters (D-CA)</a>
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Amend the Social Security Act to require the establishment and annual updating of publicly available drug pricing dashboards including: the Medicare Part B Drug and Biologic Dashboard, the Medicare Covered Part D Drug Dashboard, and the Medicaid Covered Outpatient Drug Dashboard.	<a href="#">Rep. Peters (D-CA)</a>
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Require that direct-to-consumer advertisements for drugs and biologics provide 'truthful and non-misleading pricing information.'	<a href="#">Rep. Peters (D-CA)</a>
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Build Back Better Act; Introduced 09/27/2021] Require the Secretary of HHS to publish the upper limit price, also known as the maximum fair price, for negotiations with drug manufacturers.	<a href="#">Rep. Yarmuth (D-KY)</a>
Limit Price Inflation	Impose a financial disincentive on manufacturers for drug prices that are increasing faster than inflation. Examples include excise taxes and rebates	[Freedom from Price Gouging Act; Introduced 04/20/2021] Require drug manufacturers to pay a Medicare part B rebate for certain drugs if the price of such drugs increases faster than inflation.	<a href="#">Rep. Porter (D-CA)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Limit Price Inflation	Impose a financial disincentive on manufacturers for drug prices that are increasing faster than inflation. Examples include excise taxes and rebates	[Elijah E. Cummings Lower Drug Costs Now Act; Introduced 04/22/2021] Enact inflation rebate if drug company has raised the price of a drug in Medicare Part B or D above rate of inflation since 2016.	<a href="#">Rep. Pallone (D-NJ)</a>
Limit Price Inflation	Impose a financial disincentive on manufacturers for drug prices that are increasing faster than inflation. Examples include excise taxes and rebates	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Require drug manufacturers to provide rebates to Medicare Part B for single source drugs with prices increasing faster than inflation.	<a href="#">Rep. Peters (D-CA)</a>
Limit Price Inflation	Impose a financial disincentive on manufacturers for drug prices that are increasing faster than inflation. Examples include excise taxes and rebates	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Requires drug manufacturers to provide rebates to Medicare Part D for drugs with prices increasing faster than inflation.	<a href="#">Rep. Peters (D-CA)</a>
Limit Price Inflation	Impose a financial disincentive on manufacturers for drug prices that are increasing faster than inflation. Examples include excise taxes and rebates	[Build Back Better Act; Introduced 09/27/2021] Require drug manufacturers to provide rebates to Medicare Parts B and D when drug prices are increasing faster than inflation.	<a href="#">Rep. Yarmuth (D-KY)</a>
Reduce costs and improve access for patients	Allow for the importation of FDA-approved drugs from other countries	[Affordable and Safe Prescription Drug Importation Act; Introduced 03/23/2021] Allow for the importation of affordable and safe drugs by wholesalers, pharmacies, and individuals.	<a href="#">Sen. Sanders (I-VT)</a>
Reduce costs and improve access for patients	Allow for the importation of FDA-approved drugs from other countries	[Affordable Medications Act; Introduced 05/27/2021] Permit the importation of qualifying prescription drugs into the United States by certified wholesale distributors, pharmacies, and individuals.	<a href="#">Sen. Smith (D-MN)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Reduce costs and improve access for patients	Allow the Medicare program to negotiate with manufacturers	[Affordable Medications Act; Introduced 05/27/2021] Allow the Secretary to negotiate with drug manufacturers the prices that may be charged to Medicare Part D and Medicare Advantage prescription drug plans for applicable covered Part D drugs.	<a href="#">Sen. Smith (D-MN)</a>
Reduce costs and improve access for patients	Alternative payment plans	[Lower Costs, More Cures Act of 2021; Introduced 04/21/2021] Allow certain enrollees of Medicare PDP and MA-PD plans to spread out payment of coinsurance into monthly installments under certain circumstances.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>
Reduce costs and improve access for patients	Alternative payment plans	[Elijah E. Cummings Lower Drug Costs Now Act; Introduced 04/22/2021] Allow certain enrollees under part D to spread out their coinsurance payments over periodic installments.	<a href="#">Rep. Pallone (D-NJ)</a>
Reduce costs and improve access for patients	Alternative payment plans	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Allow beneficiaries enrolled in Medicare Part D and Medicare Advantage prescription drug plans who incur a significant portion of costs towards annual out-of-pocket threshold to have their monthly out-of-pocket cost-sharing capped and paid in monthly installments.	<a href="#">Rep. Peters (D-CA)</a>
Reduce costs and improve access for patients	Alternative payment plans	[Build Back Better Act; Introduced 09/27/2021] Allow beneficiaries enrolled in Medicare Part D and Medicare Advantage prescription drug plans who incur costs equal to or above the annual out-of-pocket threshold while dispensing the first fill of a covered Part D drug to spread cost-sharing and pay for such a drug in periodic installments.	<a href="#">Rep. Yarmuth (D-KY)</a>
Reduce costs and improve access for patients	Establish pricing requirements for drugs developed with federal support	[Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2021; Introduced 08/10/2021] Require those who engage in federally funded research and development to enter into reasonable pricing agreements with the Secretary of HHS for any biomedical products or services that result.	<a href="#">Rep. DeFazio (D-OR)</a>
Reduce costs and improve access for patients	Include price concessions in POS for patients enrolled in Medicare/Medicaid	[Pharmacy DIR Reform To Reduce Senior Drug Costs Act; Introduced 05/25/2021] Require pharmacy-negotiated price concessions, payments, and fees to be included in negotiated prices at the point-of-sale under Medicare Part D.	<a href="#">Rep. Welch (D-VT)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Reduce costs and improve access for patients	Include price concessions in POS for patients enrolled in Medicare/Medicaid	[The Insulin Cost Reduction Act; Introduced 10/19/2021] Prohibit price concessions between drug manufacturers and prescription drug and Medicare Advantage prescription drug plans for insulin products unless price concessions are passed through to beneficiaries at point-of-sale.	<a href="#">Rep. Grothman (R-WI)</a>
Reduce costs and improve access for patients	Increase beneficiary choices under Medicare	[PACE Part D Choice Act of 2021; Introduced 08/06/2021] Require that Medicare-only PACE program enrollees have access to a choice between multiple prescription drug plans under Medicare Part D.	<a href="#">Rep. Blumenauer (D-OR)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Lower Costs, More Cures Act of 2021; Introduced 04/21/2021] Eliminate the part D benefit coverage gap and lower the out-of-pocket threshold to \$3,100 beginning in 2022.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Lower Costs, More Cures Act of 2021; Introduced 04/21/2021] Sunset the current part D manufacturer discount program and establish a new manufacturer discount program where manufacturers are required to provide beneficiaries who have met their deductible with a 10% discount off the negotiated price at point of sale.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Lower Costs, More Cures Act of 2021; Introduced 04/21/2021] Establish a monthly out-of-pocket cap for insulin products and supplies under a PDP or MA-PD plan.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Elijah E. Cummings Lower Drug Costs Now Act; Introduced 04/22/2021] Eliminate the part D benefit coverage gap by lowering the out-of-pocket threshold to \$2,000 beginning in 2024.	<a href="#">Rep. Pallone (D-NJ)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Elijah E. Cummings Lower Drug Costs Now Act; Introduced 04/22/2021] Sunset the current manufacturer coverage gap discount program and introduce a new manufacturer drug discount program. Require manufacturers to provide a discounted price to applicable beneficiaries of 10% of the part D negotiated price for spending below the \$2,000 threshold, and a discounted price of 30% of the negotiated price for spending above the threshold.	<a href="#">Rep. Pallone (D-NJ)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Lowering Medicare Premiums and Prescription Drug Costs Act; Introduced 05/26/2021] Establish a program under Medicare to assist low-income Medicare	<a href="#">Sen. Casey (D-PA)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		beneficiaries with premiums, coinsurance, deductibles, and other costs. Currently, such assistance is provided through Medicare Savings Programs, which are administered by state Medicaid programs.	
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Affordable Medications Act; Introduced 05/27/2021] Require drug manufacturers to provide rebates for covered Part D drugs dispensed to low-income individuals.	<a href="#">Sen. Smith (D-MN)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Affordable Medications Act; Introduced 05/27/2021] Cap cost-sharing for prescription drugs under a health plan at \$250 per month for each enrolled individual or \$500 per month for each family.	<a href="#">Sen. Smith (D-MN)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Infrastructure Investment and Jobs Act; Introduced 06/04/2021] Set moratorium on the implementation of a rule relating to the eliminating the anti-kickback statute safe harbor protection for prescription drug rebates.	<a href="#">Rep. DeFazio (D-OR)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Insulin Access for All Act of 2021; Introduced 06/24/2021] Eliminate cost sharing for covered insulins under Medicare Part D or covered outpatient drugs under Medicaid.	<a href="#">Rep. Rush (D-IL)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Cancer Drug Parity Act of 2021; Introduced 07/09/2021] Require group health plans to provide cost sharing for oral anticancer drugs on terms no less favorable than the cost sharing provided for anticancer medications administered by a health care provider.	<a href="#">Rep. Higgins (D-NY)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Capping Drug Costs for Seniors Act of 2021; Introduced 07/13/2021] Reduction of annual out of pocket cost threshold for Medicare Part D and elimination of beneficiary cost sharing above this threshold.	<a href="#">Rep. Horsford (D-NV)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Seniors Prescription Drug Relief Act; Introduced 07/13/2021] Redesign of Medicare Part D to establish a monthly out-of-pocket cost sharing maximum.	<a href="#">Sen. Cassidy (R-LA)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Matt's Act; Introduced 07/29/2021] Limit the price of insulin drugs for participants, beneficiaries, and enrollees enrolled in group or individual health insurance coverage and group health plans as well as uninsured individuals who have diabetes.	<a href="#">Rep. Fortenberry (R-NE)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Matt's Act; Introduced 07/29/2021] Capping the out-of-pocket cost for insulin for enrollees of group healthplan diagnosed with diabetes.	<a href="#">Rep. Fortenberry (R-NE)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Choose Medicare Act; Introduced 08/13/2021] Cap the annual out-of-pocket cost sharing that a beneficiary is responsible for under Medicare parts A and B.	<a href="#">Rep. Gomez (D-CA)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Choose Medicare Act; Introduced 08/13/2021] Allow the Secretary of HHS and the National Association of Insurance Commissioners to create a program that allows states to provide assistance to reduce out-of-pocket costs for beneficiaries of qualified health plans in the individual market.	<a href="#">Rep. Gomez (D-CA)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Lowering Medicare Premiums and Prescription Drug Costs Act; Introduced 08/24/2021] Expansion of patient assistance for out-of-pocket costs under Medicare Part D for low income seniors and those with disabilities.	<a href="#">Rep. Schneider (D-IL)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Establish that the payment amount for a covered drug administration service be the same and will apply if the drug administration service is provided by an off-campus outpatient department of the provider.	<a href="#">Rep. Peters (D-CA)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Establish new deductible thresholds based on beneficiaries' income as a percentage of the federal policy line for Medicare Part D beneficiaries.	<a href="#">Rep. Peters (D-CA)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Establishes low income subsidies for beneficiaries enrolled in Medicare Part D and Medicare Advantage prescription drug plans.	<a href="#">Rep. Peters (D-CA)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Establish a monthly cap on out of pocket costs on insulin products and supplies for beneficiaries covered under prescription drug plans or Medicare Advantage prescription drug plans.	<a href="#">Rep. Peters (D-CA)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Build Back Better Act; Introduced 09/27/2021] Close Medicaid coverage gap in states that have not expanded Medicaid.	<a href="#">Rep. Yarmuth (D-KY)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Build Back Better Act; Introduced 09/27/2021] Require drug manufacturers to provide discounts to Medicare Part D and Medicare Advantage Prescription Drug plan beneficiaries that have incurred costs that exceed their annual deductible for the year.	<a href="#">Rep. Yarmuth (D-KY)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[HELP Copays Act; Introduced 11/1/2021] Amend the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans.	<a href="#">Rep. McEachin (D-VA)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Capping Prescription Costs Act of 2021; Introduced 12/8/2021] Place cap on prescription drug cost-sharing of \$250 per month per individual or \$500 per month per family.	<a href="#">Sen. Warnock (D-GA)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Cutting Medicare Prescription Drug Prices in Half Act; Introduced 02/09/2022] Establishing a cap for covered prescription drugs under Medicare parts B and D.	<a href="#">Sen. Sanders (I-VT)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Affordable Insulin Now Act; Introduced 02/17/2022] Implement appropriate cost-sharing for insulin products that are covered under Medicare Part D and private health plans.	<a href="#">Sen. Warnock (D-GA)</a>
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Insulin Savings for Patients Act; Introduced 02/18/2022] Cap cost-sharing for insulin for month's supply of selected insulin products at \$35 or %25 of a private health insurance plan's negotiated price (whichever is less), and under the Medicare prescription drug benefit at \$35 between October 2022 and January 2024, and under the same rules for private health insurances starting in 2024.	<a href="#">Rep. Burgess (R-TX)</a>
Reduce costs and improve access for patients	Utilize international reference pricing	[End Price Gouging for Medications Act; Introduced 04/22/2021] Require the Secretary of Health and Human Services to establish international reference prices for prescription drugs. Retail prices of covered drugs under federal health programs may not exceed the established reference prices.	<a href="#">Rep. Welch (D-VT)</a>
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Health Care Improvement Act of 2021; Introduced 02/22/2021] Grant Medicare the authority to negotiate prescription drugs.	<a href="#">Sen. Warner (D-VA)</a>
Reduce costs for government health programs	Allow the Medicare program to	[Medicare-X Choice Act of 2021; Introduced 02/23/2021] Grant Medicare the authority to negotiate prescription drugs.	<a href="#">Sen. Bennet (D-CO)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
	negotiate with manufacturers		
Reduce costs for government health programs Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Medicare Prescription Drug Price Negotiation Act of 2021; Introduced 03/18/2021] Require the Secretary of HHS to negotiate prices for covered drugs under part D.	<a href="#">Rep. Welch (D-VT)</a>
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Medicare Drug Price Negotiation Act; Introduced 03/23/2021] Grant Medicare the authority to negotiation part D drug prices and establish and apply a formulary by the Secretary of HHS under part D.	<a href="#">Sen. Sanders (I-VT)</a>
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Medicare Negotiation and Competitive Licensing Act of 2021; Introduced 07/29/2021] Require the Secretary of HHS to negotiate drug prices with drug manufacturers for drugs covered under Medicare.	<a href="#">Rep. Dogget (D-TX)</a>
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Choose Medicare Act; Introduced 08/13/2021] Allow the Secretary of HHS to negotiate with drug manufacturers for fair prices for Medicare prescription drugs.	<a href="#">Rep. Gomez (D-CA)</a>
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Establishment of Medicare Part B payment rules for drugs and biologics that are to become negotiation-eligible. The Secretary will work with each drug manufacturer to negotiate a maximum allowable cost for each negotiation-eligible drug.	<a href="#">Rep. Peters (D-CA)</a>
Reduce costs for government health programs	Alter payment rates	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Establish that the payments amount for a covered drug administration service be the same and will apply if the drug administration service is provided by an off-campus outpatient department of the provider.	<a href="#">Rep. Peters (D-CA)</a>
Reduce costs for government health programs	Implement pass-through pricing requirement to plan sponsors associated with government health programs	[Lower Costs, More Cures Act of 2021; Introduced 04/21/2021] Require pass-through pricing under Medicaid.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Reduce costs for government health programs	Implement pass-through pricing requirement to plan sponsors associated with government health programs	[Drug Price Transparency in Medicaid Act of 2021; Introduced 12/1/2021] Require pass-through drug pricing between the State and pharmacy benefit managers or managed care entities in the Medicaid program.	<a href="#">Rep. Carter (R-GA)</a>
Reduce costs for government health programs	Incentivize physician prescribing of lower cost drugs	[Lower Costs, More Cures Act of 2021; Introduced 04/21/2021] Vary payments for certain part B drugs based on percentile ranking of per beneficiary allowed charges. Per beneficiary charge equals the total part B payment divided by the number of drug beneficiaries. Higher percentile ranking drugs would have a lower ASP percentage markup. Percentage markup would vary between 4-10%.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>
Reduce costs for government health programs	Increasing manufacturer rebates to government programs	[Medicare Drug Price Negotiation Act; Introduced 03/23/2021] Require manufacturers to provide rebates for drugs dispensed to low-income individuals.	<a href="#">Sen. Sanders (I-VT)</a>
Reduce costs for government health programs	Increasing manufacturer rebates to government programs	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Require a Medicaid drug rebate for covered outpatient drugs.	<a href="#">Rep. Peters (D-CA)</a>
Reduce costs for government health programs	Increasing manufacturer rebates to government programs	[Lower Costs, More Cures Act of 2021; Introduced 04/21/2021] Apply Medicaid drug rebate requirements to drugs provided as part of outpatient hospital services.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>
Reduce costs for government health programs	Increasing manufacturer rebates to government programs	[Drug Price Transparency Act of 2021; Introduced 04/29/2021] Remove previous safe harbor protection for rebates involving prescription drugs. Establishes a new safe harbor protection that allows a rebate from a drug manufacturer to a health insurer or pharmacy benefit manager to be exempt only if the rebate (1) is disclosed to the consumer at the point of sale, or (2) is a flat fee paid for pharmacy benefit management services.	<a href="#">Sen. Braun (R-IN)</a>
Reduce costs for government health programs	Increasing manufacturer rebates to government programs	[Fair Drug Prices for Kids Act; Introduced 10/19/2021] Allow states to incorporate rebate requirements to help reduce costs associated with prescription drugs for the state's child health plan.	<a href="#">Rep. Wild (D-PA)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Reduce costs for government health programs	Limiting add-on payments to providers	[Lower Costs, More Cures Act of 2021; Introduced 04/21/2021] Establish a maximum add-on payment for drugs and biologics.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>
Reduce costs for government health programs	Limiting add-on payments to providers	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Lowering maximum add-on payments for drugs and biologics under Medicare Part B.	<a href="#">Rep. Peters (D-CA)</a>
Reduce costs for government health programs	Require rebates for amount of drug discarded for medicines packaged in single-dose vials	[Lower Costs, More Cures Act of 2021; Introduced 04/21/2021] Require manufacturers of certain single-dose container or single-use package drugs under part B to provide refunds for amounts of discarded drugs.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>
Reduce costs for government health programs	Require rebates for amount of drug discarded for medicines packaged in single-dose vials	[Infrastructure Investment and Jobs Act; Introduced 06/04/2021] Require manufacturers of certain single-dose container or single-use package drugs payable under Medicare Part B to provide refunds for discarded amounts of such drugs.	<a href="#">Rep. DeFazio (D-OR)</a>
Reduce costs for government health programs	Require rebates for amount of drug discarded for medicines packaged in single-dose vials	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Require manufacturers of single-dose packaged drugs to provide refunds of discarded amounts to Medicare Part B.	<a href="#">Rep. Peters (D-CA)</a>
Reduce costs for government health programs	Share risk between payers and manufacturers	[Lower Costs, More Cures Act of 2021; Introduced 04/21/2021] Allow the option for states to pay for risk-sharing value-based payment agreements for covered outpatient drugs under Medicaid.	<a href="#">Rep. McMorris Rodgers (R-WA)</a>
Reduce costs for government health programs	Share risk between payers and manufacturers	[Reduced Costs and Continued Cures Act of 2021; Introduced 09/10/2021] Establish option for risk sharing value-based agreements between state Medicaid programs and drug manufacturers.	<a href="#">Rep. Peters (D-CA)</a>
Reduce costs for government health programs	Utilize international reference pricing	[Prescription Drug Price Relief Act of 2021; Introduced 03/23/2021] End government-granted monopolies for manufacturers that charge drug prices higher than the median prices for drugs in other countries.	<a href="#">Sen. Sanders (I-VT)</a>
Reduce costs for government health programs	Utilize international reference pricing	[End Price Gouging for Medications Act; Introduced 04/22/2021] Require the Secretary of HHS to establish reference prices for drugs under Federal health programs.	<a href="#">Sen. Merkley (D-OR)</a>

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Reduce costs for government health programs	Utilize international reference pricing	[Elijah E. Cummings Lower Drug Costs Now Act; Introduced 04/22/2021] Establish a Fair Price Negotiation Program where the Secretary enters into agreements with the manufacturers of selected drugs to negotiate for lower prices. Negotiated price may not exceed 120% of the price in six other reference countries.	<a href="#">Rep. Pallone (D-NJ)</a>
Reduce costs for government health programs	Utilize international reference pricing	[Build Back Better Act; Introduced 09/27/2021] Establish a Fair Price Negotiation Program where the Secretary enters into agreements with the manufacturers of selected drugs to negotiate for lower prices. The negotiated price is related to the average international market price as calculated by the net average drug price in six other reference countries.	<a href="#">Rep. Yarmuth (D-KY)</a>